Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
26.37
+0.67 (2.61%)
May 8, 2025, 4:00 PM EDT - Market closed

Janux Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-77.74-68.99-58.29-63.06-32.67-6.78
Upgrade
Depreciation & Amortization
2.052.061.960.840.110.01
Upgrade
Loss (Gain) From Sale of Assets
----0-
Upgrade
Loss (Gain) From Sale of Investments
-13.02-10.59-7.69-2.18-0.17-
Upgrade
Stock-Based Compensation
38.133.0220.0117.26.910.07
Upgrade
Other Operating Activities
-----1.94
Upgrade
Change in Accounts Receivable
0.52---8-8
Upgrade
Change in Accounts Payable
0.41.580.28-0.292.140.01
Upgrade
Change in Unearned Revenue
-0.97-1.71-5.921.76-2.148
Upgrade
Change in Other Net Operating Assets
4.670.81-0.912.810.840.38
Upgrade
Operating Cash Flow
-46-43.81-50.58-42.92-16.98-4.37
Upgrade
Capital Expenditures
-0.53-0.36-1.85-6.45-1.48-
Upgrade
Investment in Securities
-484.14-257.66-39.3464.71-339.48-
Upgrade
Investing Cash Flow
-484.68-258.02-41.1958.27-340.96-
Upgrade
Short-Term Debt Issued
-----2.5
Upgrade
Total Debt Issued
-----2.5
Upgrade
Net Debt Issued (Repaid)
-----2.5
Upgrade
Issuance of Common Stock
712.48713.2459.550.5205.980.07
Upgrade
Other Financing Activities
-320.86----0.45-
Upgrade
Financing Cash Flow
391.62713.2459.550.5386.5211.52
Upgrade
Net Cash Flow
-139.06411.4-32.2215.8428.597.16
Upgrade
Free Cash Flow
-46.53-44.17-52.43-49.37-18.46-4.37
Upgrade
Free Cash Flow Margin
-498.44%-417.20%-648.58%-573.24%-507.51%-
Upgrade
Free Cash Flow Per Share
-0.82-0.82-1.19-1.19-0.78-4.77
Upgrade
Levered Free Cash Flow
-32.09-26.14-29.52-30.560.58-8.77
Upgrade
Unlevered Free Cash Flow
-32.09-26.14-29.52-30.560.58-8.64
Upgrade
Change in Net Working Capital
-4.37-0.914.020.23-15.625.7
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q